NAD

National Advertising Review Board Finds Certain AT&T Comparative Advertising Claims Supported; Recommends Discontinuation or Modification of Others

Internet, View, AT, Advertising, ISP, Industry, CARU, AT&T, Privacy, Compliance, Business, Xfinity, Super Fan (game show), Multimedia, Videotelephony, Council, Failure, Anxiety, NAD, AT&T U-verse, Public sector, Better Business Bureau, Television, Communications satellite, Cable television, Online shopping
Thursday, October 14, 2021 - 2:00pm

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- A panel of the National Advertising Review Board (NARB), the appellate advertising law body of BBB National Programs, has determined that AT&T Services, Inc. properly supported certain comparative advertising claims for its fiber-optic internet service in one commercial and one internet video advertisement.

Key Points: 
  • NEW YORK, Oct. 14, 2021 /PRNewswire/ -- A panel of the National Advertising Review Board (NARB), the appellate advertising law body of BBB National Programs, has determined that AT&T Services, Inc. properly supported certain comparative advertising claims for its fiber-optic internet service in one commercial and one internet video advertisement.
  • AT&T discontinue or modify one commercial which communicated unsupported claims that AT&T's fiber service is superior to cable services for videoconferencing and reliability.
  • The advertising at issue had been challenged by Comcast Cable Communications, Inc. before the National Advertising Division (NAD).
  • About the National Advertising Review Board (NARB):The National Advertising Review Board(NARB)is the appellate body for BBB National Programs' advertising self-regulatory programs.

ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021

Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Risk, An Act to exempt a particular class of securities from the Securities and Exchange Act, Ageing, NR, Security (finance), Securities Act of 1933, SEC, ChromaDex, NAD, Company, Annual report, NASDAQ, Research, Silviculture
Wednesday, October 13, 2021 - 11:33am

ET to discuss its financial results for the third quarter ended Sep. 30, 2021.

Key Points: 
  • ET to discuss its financial results for the third quarter ended Sep. 30, 2021.
  • The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
  • ChromaDex management will host an investor conference call to discuss the third quarter results and provide a general business update on Wednesday, Nov. 3, at 4:30 p.m.
  • ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Dr. David Sinclair Joins Levels as Advisor

Medical Devices, Health, Technology, Diabetes, Fitness & Nutrition, Software, Lazarus, Harvard Medical School, NAD, Book, Memory, Biotechnology, National, Biology, CGM, Diabetes, Time, Department of Genetics, University of Cambridge, SpaceX, Cancer, TIME, Research, Chromatin, Commonwealth Writers, Molecular genetics, Technology, CR, Neurodegeneration, Prediabetes, Calorie, Google, Sleep, University, Resveratrol, Awareness, Leadership, Diet, Food, Multimedia, SIRT1, Regeneration, Respiration (physiology), Mammal, Exercise, Stanford University, Sirtuin, Department, Doctor of Philosophy, Health, Longevity, Mitochondrion, Microdeletion syndrome, Learning, Partnership, Science, Biomarker, Pharmaceutical industry, News, Medical device
Tuesday, October 12, 2021 - 2:00pm

Levels , the first biosensor system to give real-time feedback on nutrition and lifestyle, today announced that leading longevity scientist Dr. David Sinclair has joined the company as a Levels Advisor .

Key Points: 
  • Levels , the first biosensor system to give real-time feedback on nutrition and lifestyle, today announced that leading longevity scientist Dr. David Sinclair has joined the company as a Levels Advisor .
  • Dr. Sinclair has been at the forefront of the latest discoveries in understanding why we age and how to slow its effects.
  • Dr. Sinclair joins an unprecedented group of thought leaders, clinicians, and researchers in metabolic health, and his expertise will help to drive awareness to the metabolic health crisis through content development and research in partnership with the Levels team.
  • View the full release here: https://www.businesswire.com/news/home/20211012005133/en/
    Dr. David Sinclair Joins Levels as Advisor (Photo: Business Wire)
    Im excited to work with Levels Health to empower people with the tools to optimize their bodies and help achieve longer healthspans and lifespans, says Dr. Sinclair.

EZZ Has Opened up Global Retail Channels Such as Costco

Silver, Costco, NAD, HPV, Growth, Industry, University of Auckland, COSTCO, Enzyme, Auckland University of Technology, Gene, CEO, EZZ, NMN, Helicobacter pylori, Partnership, Sale, Research, Australian Securities Exchange, Amusement arcade
Sunday, October 10, 2021 - 2:17am

To view an enhanced version of this graphic, please visit:

Key Points: 
  • To view an enhanced version of this graphic, please visit:
    Fernando Rodriguez, CEO of EZZ, said: "EZZ is pleased to confirm that EZZ brand NMN products are now available in 13 Costco stores in Australia and 13 Costco stores in Taiwan, China.
  • The EZZ NAD STAY YOUNG item is the only NMN on sale at COSTCO.
  • "In February, COSTCO enters into a strategic partnership with EZZ and confirms that EZZ would be listed as COSTCO's brand.
  • The strong strength of EZZ is the reason why COSTCO chose EZZ as the only brand in the NMN industry among many NMN brands.

ChromaDex, Inc. Discontinues Advertising Claims for Tru Niagen Dietary Supplement Following National Advertising Division Challenge

NAD, Pro Football Hall of Fame, Privacy, Advertising, Multimedia, NFL, 1964 NFL Draft, CARU, Association of National Advertisers, Cell, ChromaDex, Council, Dietary supplement
Tuesday, October 5, 2021 - 2:00pm

NEWYORK, Oct. 5, 2021 /PRNewswire/ --Following a BBB National Programs National Advertising Division (NAD) challenge, brought as part of NAD's routine monitoring of national advertising for truth and transparency, the advertiser ChromaDex, Inc. permanently discontinued advertising claims regarding the performance benefits of its Tru Niagen dietary supplement.

Key Points: 
  • NEWYORK, Oct. 5, 2021 /PRNewswire/ --Following a BBB National Programs National Advertising Division (NAD) challenge, brought as part of NAD's routine monitoring of national advertising for truth and transparency, the advertiser ChromaDex, Inc. permanently discontinued advertising claims regarding the performance benefits of its Tru Niagen dietary supplement.
  • All BBB National Programs case decision summaries can be found in the case decision library .
  • About BBB National Programs:BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard.
  • About the National Advertising Division:TheNational Advertising Division (NAD) of BBB National Programsprovidesindependent self-regulationand dispute resolution services,guidingthe truthfulness of advertising across the U.S. NADreviews national advertising in all media and its decisions set consistent standards foradvertisingtruth and accuracy, delivering meaningful protection toconsumersand leveling the playing field for business.

ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth

Biotechnology, Pharmaceutical, Other Retail, Health, Specialty, Fitness & Nutrition, Discount, Variety, Retail, Elysium, NAD, Securities Act of 1933, Risk, Annual report, Ageing, NASDAQ, NR, A.S. Watson Group, SEC, Company, European Union, District court, Growth, Union, Research, Safety, Securities Exchange Act of 1934, Government, Central District, Pharmaceutical industry, Security (finance)
Friday, October 1, 2021 - 11:33am

Based on the jurys verdict, Elysium and Mark Morris will be required to pay ChromaDex approximately $2.25 to $2.50 million in damages and estimated interest.

Key Points: 
  • Based on the jurys verdict, Elysium and Mark Morris will be required to pay ChromaDex approximately $2.25 to $2.50 million in damages and estimated interest.
  • It took nearly five years and has been challenging for both companies, but the jurys decision finally holds Elysium accountable for paying what it owes, said ChromaDex CEO Rob Fried.
  • The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.
  • ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China

Other Retail, Other Health, Health, General Health, Specialty, Women, Seniors, Men, Retail, Fitness & Nutrition, Consumer, Ministry of Social Affairs, Securities Act of 1933, Partnership, Watsons, Nicotinamide mononucleotide, Risk, Annual report, Drug Quality and Security Act, State, Economy, Ageing, NASDAQ, Therapeutic Goods Administration, Sale, FDA, NR, JD, National Bureau of Asian Research, Central China, TGA, Sinopharm Group, SEC, State-owned Assets Supervision and Administration Commission, Marketing, SASAC, Royal commission, Industry, Company, WeChat, Health Canada, State Council, Tru, Research, National Bureau of Statistics of China, European Commission, NMN, ChromaDex, Securities Exchange Act of 1934, United Nations Department of Economic and Social Affairs, NAD, Pharmaceutical industry
Wednesday, September 29, 2021 - 11:37am

ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (Sinopharm Xingsha) to conduct cross-border sales of Tru Niagen in mainland China.

Key Points: 
  • ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (Sinopharm Xingsha) to conduct cross-border sales of Tru Niagen in mainland China.
  • Sinopharm Xingsha is a subsidiary of Sinopharm Group, with businesses including pharmaceutical manufacturing, marketing and distribution of drugs, and food supplements and healthcare products.
  • Sinopharm Xingsha and ChromaDex will also collaborate to secure Health Food Registration in China.
  • ChromaDex delivers Niagen as the sole active ingredient in its consumer product Tru Niagen available at www.truniagen.com and through partnerships with global retailers and distributors.

NAD Finds Certain Environmental Benefit Claims for Quilted Northern Ultra Soft & Strong Bathroom Tissue Supported; Recommends Modification of Others

Disclosure, NAD, Football, Tree, Georgia-Pacific, Privacy, Water, Advertising, Lists of record labels, Multimedia, Drinking water, Environment, Premium, Better Business Bureau, CARU, Technology, Association of National Advertisers, Council, Tissue paper, Dietary supplement, Recycling, Marketing, Online shopping, Public relations
Tuesday, September 28, 2021 - 2:00pm

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- The National Advertising Division (NAD) of BBB National Programs determined that Georgia-Pacific Consumer Products LP provided a reasonable basis for certain the environmental benefit claims referenced below for its Quilted Northern Ultra Soft & Strong Bathroom Tissue, including tree-planting claims, energy-efficient-manufacturing claims, real-life energy and water savings examples, and sustainability claims, and that all such claims were substantiated. NAD recommended, however, that several certain of these claims be modified to more clearly disclose the basis for the claims and to avoid communicating unsupported messages.

Key Points: 
  • NAD recommended, however, that several certain of these claims be modified to more clearly disclose the basis for the claims and to avoid communicating unsupported messages.
  • The claims, which appeared on the advertiser's Quilted Northern website and product packaging, were challenged by NAD as part of its independent routine monitoring of truth and transparency in U.S. national advertising.
  • NAD determined that the advertiser provided a reasonable basis for the claims:
    "Our proprietary, efficient manufacturing technology squeezes out more water from the paper before drying.
  • "If just one household switched to Quilted Northern Ultra Soft & Strong for a year, it would save enough energy to:
    Watch 21 college football games.

Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Biotechnology, Therapy, Inflammation, Society, NAD, Cancer, Patient, Annual general meeting, SCCL, Biology, American Society of Clinical Oncology, Managing editor, ASCO, Medicine, Ribon, Disease, Enzyme, Industry, Lung, Fine chemical, Pharmaceutical industry
Monday, September 27, 2021 - 3:30pm

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced it has been named by Fierce Biotech as one of 2021s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced it has been named by Fierce Biotech as one of 2021s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
  • We are thrilled to be recognized by Fierce Biotech among the industrys leading innovators, reflecting the potential of our novel pipeline and approach.
  • Speaking with this years class of Fierce 15 winners showed us that not even a global pandemic can stop incredible innovations in medicine.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

GoodAccess Cloud VPN With Zero-Trust Access Control Raised $1M in Seed Funding From Nation 1

Software as a service, Secure Access Service Edge, GLOBE, Nation, Maintenance, NAD, Software Defined Perimeter, CEO, Gartner, Internet, Technology, SASE, VPN, Cryptocurrency, Video game
Wednesday, September 22, 2021 - 2:00pm

GoodAccess is a cloud service that addresses this issue by enabling businesses to create a virtual privatenetwork with identity-based access control ( Software Defined Perimeter )in less than 10 minutes.

Key Points: 
  • GoodAccess is a cloud service that addresses this issue by enabling businesses to create a virtual privatenetwork with identity-based access control ( Software Defined Perimeter )in less than 10 minutes.
  • When connected to this network, employees can securely access applications, systems and data from anywhere.
  • As traditional VPN with static IP technology evolves, GoodAccess enforces security on a user-to-application level by building bullet-proof micro-perimeters with identity-based access control.
  • GoodAccess has the best conditions to become a game-changer that is innovating the way how modern businesses run their networks and secure remote access from anywhere.